Contraception in Chronic Kidney Disease and Renal Transplantation

  • Elizabeth SchmidtEmail author
  • Sarah L. Pachtman
  • Justin T. Diedrich


Due to the increase in the chronic kidney disease and transplant population, contraception counseling is essential in preventing unplanned pregnancies during the pre- and post-transplant period. Unintended pregnancy can have devastating effects on both mother and fetus. The physician must work with the patient to find the best method of contraception, taking into account patient preference as well as medical comorbidities. The LNG-IUS is an ideal option for the CKD and transplant patient as it is a first-line method, will help decrease monthly blood loss, and is easily reversible. In addition to the IUD, the ENG-implant is a good progestin-only method due to its high efficacy and ease of use. Individual bleeding patterns may vary but can be treated. Combined hormonal methods may be appropriate on a case-by-case basis, but have higher failure rates. If pregnancy occurs and termination is desired, the decision for an inpatient versus outpatient procedure will depend on the individual’s clinical status. Consultation with a family planning specialist is advised. Most women will not be candidates for medical termination.


Contraception in chronic kidney disease Renal transplantation and contraception Contraception and renal transplantation Chronic kidney disease and contraception Pregnancy and chronic kidney disease Hypertension in chronic kidney disease 


  1. 1.
    Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008–2011. N Engl J Med. 2016;374(9):843–52.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Watnick S, Rueda J. Reproduction and contraception after kidney transplantation. Curr Opin Obstet Gynecol. 2008;20(3):308–12.PubMedCrossRefGoogle Scholar
  3. 3.
    Sachdeva M, et al. Pregnancy outcomes in women on hemodialysis: a national survey. Clin Kidney J. 2017;10(2):276–81.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Deshpande NA, et al. Pregnancy outcomes in kidney transplant recipients: a systematic review and meta-analysis. Am J Transplant. 2011;11(11):2388–404.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    McKay DB, et al. Reproduction and transplantation: report on the AST consensus conference on reproductive issues and transplantation. Am J Transplant. 2005;5(7):1592–9.CrossRefGoogle Scholar
  6. 6.
    Curtis KM, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(3):1–103.PubMedCrossRefGoogle Scholar
  7. 7.
    Curtis KM, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(4):1–66.PubMedCrossRefGoogle Scholar
  8. 8.
    Stehman-Breen C, et al. Pharmacokinetics of oral micronized beta-estradiol in postmenopausal women receiving maintenance hemodialysis. Kidney Int. 2003;64(1):290–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception. Contraception. 1998;57(5):315–24.CrossRefGoogle Scholar
  10. 10.
    Heinemann LA, et al. Oral progestogen-only contraceptives and cardiovascular risk: results from the transnational study on oral contraceptives and the health of young women. Eur J Contracept Reprod Health Care. 1999;4(2):67–73.PubMedCrossRefGoogle Scholar
  11. 11.
    Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet. 1999;354(9190):1610–1.PubMedCrossRefGoogle Scholar
  12. 12.
    Diedrich JT, et al. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol. 2015;212(1):50 e1–8.CrossRefGoogle Scholar
  13. 13.
    Pakarinen P, Luukkainen T. Treatment of menorrhagia with an LNG-IUS. Contraception. 2007;75(6 Suppl):S118–22.PubMedCrossRefGoogle Scholar
  14. 14.
    Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol. 1990;97(8):690–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Stefanski A, et al. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int. 1996;50(4):1321–6.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Benagiano GDE, Goldzieher JW, Gray R, Apelo R, Bergstein N, JC DS, Devi PK, Kesseru E, Koetsawang S, Ojo OA, Gupta AN, Pretnar A, Toppozada HK. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethisterone oenanthate and medroxyprogesterone acetate: 2. Bleeding patterns and side effects. Contraception. 1978;17(5):395–406.CrossRefGoogle Scholar
  17. 17.
    Nilsson CG, et al. Two years’ experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study. Fertil Steril. 1983;39(2):187–92.PubMedCrossRefGoogle Scholar
  18. 18.
    McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception. 1994;50(6 Suppl 1):S1–195.PubMedGoogle Scholar
  19. 19.
    Mansour D, et al. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care. 2008;13(Suppl 1):13–28.PubMedCrossRefGoogle Scholar
  20. 20.
    Laifer SA, et al. Pregnancy and liver transplantation. Obstet Gynecol. 1990;76(6):1083–8.PubMedGoogle Scholar
  21. 21.
    Mastrobattista JM, Gomez-Lobo V. Society for Maternal Fetal Medicine, Pregnancy after solid organ transplantation. Obstet Gynecol. 2008;112(4):919–32.CrossRefGoogle Scholar
  22. 22.
    Sibanda N, et al. Pregnancy after organ transplantation: a report from the UK transplant pregnancy registry. Transplantation. 2007;83(10):1301–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Murray JE, et al. Successful pregnancies after human renal transplantation. N Engl J Med. 1963;269:341–3.PubMedCrossRefGoogle Scholar
  24. 24.
    Coscia LA, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2010:65–85.Google Scholar
  25. 25.
    Armenti VT, et al. Report from the National Transplantation Pregnancy Registry: outcomes of pregnancy after transplantation. Clin Transpl. 2006:57–70.Google Scholar
  26. 26.
    Rose C, et al. Timing of pregnancy after kidney transplantation and risk of allograft failure. Am J Transplant. 2016;16(8):2360–7.PubMedCrossRefGoogle Scholar
  27. 27.
    French VA, et al. Contraception and fertility awareness among women with solid organ transplants. Obstet Gynecol. 2013;122(4):809–14.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Rafie S, et al. Contraceptive use in female recipients of a solid-organ transplant. Prog Transplant. 2014;24(4):344–8.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Hatcher RA, Trussell J, Nelson A, Cates W, Kowal D, Policar M. Contraceptive technology. 20th ed. Atlanta: Ardent Media; 2011.Google Scholar
  30. 30.
    Winner B, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998–2007.PubMedCrossRefGoogle Scholar
  31. 31.
    Diedrich JT, et al. Three-year continuation of reversible contraception. Am J Obstet Gynecol. 2015;213(5):662 e1–8.CrossRefGoogle Scholar
  32. 32.
    Hricik DE. Transplant immunology and immunosuppression: core curriculum 2015. Am J Kidney Dis. 2015;65(6):956–66.PubMedCrossRefGoogle Scholar
  33. 33.
    Hart A, et al. OPTN/SRTR 2016 annual data report: kidney. Am J Transplant. 2018;18(Suppl 1):18–113.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Ramhendar T, Byrne P. Use of the levonorgestrel-releasing intrauterine system in renal transplant recipients: a retrospective case review. Contraception. 2012;86(3):288–9.CrossRefGoogle Scholar
  35. 35.
    Fong YF, Singh K. Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient. Contraception. 1999;60(1):51–3.PubMedCrossRefGoogle Scholar
  36. 36.
    Bahamondes MV, et al. Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas. Contraception. 2011;84(5):e11–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Tepper NK, et al. Safety of intrauterine devices among women with HIV: a systematic review. Contraception. 2016;94(6):713–24.PubMedCrossRefGoogle Scholar
  38. 38.
    Kim CR, et al. Immunologic evaluation of the endometrium with a levonorgestrel intrauterine device in solid organ transplant women and healthy controls. Contraception. 2016;94(5):534–40.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Juliato CRT, Stahlschmidt P, Fernandes A, Monteiro I, Bahamondes L. A case series on the use of levonorgestrel 52 mg intrauterine system after organ transplant. Contraception. 2018;98(3):252–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Zerner J, et al. Intrauterine contraceptive device failures in renal transplant patients. J Reprod Med. 1981;26(2):99–102.Google Scholar
  41. 41.
    Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception. 2007;75(6 Suppl):S16–30.PubMedCrossRefGoogle Scholar
  42. 42.
    Allen RH, Cwiak CA. Contraception for the medically challenging patient. New York, NY: Springer; 2014.Google Scholar
  43. 43.
    Roger T, et al. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol. 2005;35(12):3405–13.PubMedCrossRefGoogle Scholar
  44. 44.
    Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years’ comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol. 1991;77(2):261–4.PubMedCrossRefGoogle Scholar
  45. 45.
    Farley TM, et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992;339(8796):785–8.CrossRefGoogle Scholar
  46. 46.
    Hubacher D, et al. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001;345(8):561–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Long-acting reversible contraception: implants and intrauterine devices. Practice Bulletin No. 186. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2017;130e251–69.Google Scholar
  48. 48.
    McNicholas C, et al. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. Am J Obstet Gynecol. 2017;216(6):586 e1–6.CrossRefGoogle Scholar
  49. 49.
    Wu JP, Pickle S. Extended use of the intrauterine device: a literature review and recommendations for clinical practice. Contraception. 2014;89(6):495–503.PubMedCrossRefGoogle Scholar
  50. 50.
    Mansour D, et al. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. Contraception. 2011;83(3):202–10.PubMedCrossRefGoogle Scholar
  51. 51.
    Schwallie PC, Assenzo JR. Contraceptive use – efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril. 1973;24(5):331–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Clark MK, et al. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2006;86(5):1466–74.PubMedCrossRefGoogle Scholar
  53. 53.
    Canalis E, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18(10):1319–28.PubMedCrossRefGoogle Scholar
  54. 54.
    Kavanaugh ML, Jerman J. Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014. Contraception. 2018;97(1):14–21.PubMedCrossRefGoogle Scholar
  55. 55.
    Pietrzak B, et al. Combined oral contraception in women after renal transplantation. Neuro Endocrinol Lett. 2006;27(5):679–82.PubMedGoogle Scholar
  56. 56.
    Paternoster DM, et al. The contraceptive vaginal ring in women with renal and liver transplantation: analysis of preliminary results. Transplant Proc. 2010;42(4):1162–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Jabiry-Zieniewicz Z, et al. Low-dose hormonal contraception after liver transplantation. Transplant Proc. 2007;39(5):1530–2.PubMedCrossRefGoogle Scholar
  58. 58.
    Cleland K, et al. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod. 2012;27(7):1994–2000.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Glasier AF, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010;375(9714):555–62.PubMedCrossRefGoogle Scholar
  60. 60.
    Moreau C, Trussell J. Results from pooled phase III studies of ulipristal acetate for emergency contraception. Contraception. 2012;86(6):673–80.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Glasier A, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception. 2011;84(4):363–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Paul M, Lichtenberg ES, Borgatta L, Grimes DA, Stubblefield PG, Creinin, MD. Management of Unintended and Abnormal Pregnancy: Comprehensive Abortion Care. Hoboken, NJ: John Wiley and Sons, 2009.Google Scholar
  63. 63.
    Creinin MD, Grossman DA. Medical management of first-trimester abortion. Contraception. 2014;89(3):148–61.Google Scholar
  64. 64.
    Diagnosis of abnormal uterine bleeding in reproductive-aged women. Practice Bulletin No. 128. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2012;120:197–206.Google Scholar
  65. 65.
    Munro MG, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3–13.PubMedCrossRefGoogle Scholar
  66. 66.
    Fraser IS, et al. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril. 2007;87(3):466–76.PubMedCrossRefGoogle Scholar
  67. 67.
    James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia. 2005;11(4):295–307.PubMedCrossRefGoogle Scholar
  68. 68.
    Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem. 1999;45(7):942–56.PubMedGoogle Scholar
  69. 69.
    Vladutiu AO, et al. Heterophilic antibodies interfering with radioimmunoassay. A false-positive pregnancy test. JAMA. 1982;248(19):2489–90.PubMedCrossRefGoogle Scholar
  70. 70.
    Kelekci S, et al. Comparison of transvaginal sonography, saline infusion sonography, and office hysteroscopy in reproductive-aged women with or without abnormal uterine bleeding. Fertil Steril. 2005;84(3):682–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Soguktas S, et al. Comparison of saline infusion sonohysterography and hysteroscopy in diagnosis of premenopausal women with abnormal uterine bleeding. Eur J Obstet Gynecol Reprod Biol. 2012;161(1):66–70.PubMedCrossRefGoogle Scholar
  72. 72.
    Doubilet PM. Diagnosis of abnormal uterine bleeding with imaging. Menopause. 2011;18(4):421–4.PubMedGoogle Scholar
  73. 73.
    Lionaki S, et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol. 2012;7(1):43–51.PubMedCrossRefGoogle Scholar
  74. 74.
    Kaminski P, et al. Gynecological issues after organ transplantation. Neuro Endocrinol Lett. 2008;29(6):852–6.PubMedGoogle Scholar
  75. 75.
    Kaunitz AM, et al. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2009;113(5):1104–16.PubMedCrossRefGoogle Scholar
  76. 76.
    Kaunitz AM, Inki P. The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review. Drugs. 2012;72(2):193–215.PubMedCrossRefGoogle Scholar
  77. 77.
    Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost. 2001;86(2):714–5.PubMedGoogle Scholar
  78. 78.
    Sundstrom A, et al. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the general practice Research database. BJOG. 2009;116(1):91–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Tengborn L, Blomback M, Berntorp E. Tranexamic acid – an old drug still going strong and making a revival. Thromb Res. 2015;135(2):231–42.PubMedCrossRefGoogle Scholar
  80. 80.
    Weigert AL, Schafer AI. Uremic bleeding: pathogenesis and therapy. Am J Med Sci. 1998;316(2):94–104.PubMedGoogle Scholar
  81. 81.
    Livio M, et al. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med. 1986;315(12):731–5.PubMedCrossRefGoogle Scholar
  82. 82.
    Heistinger M, et al. Effect of conjugated estrogens on platelet function and prostacyclin generation in CRF. Kidney Int. 1990;38(6):1181–6.PubMedCrossRefGoogle Scholar
  83. 83.
    Vigano G, et al. Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney Int. 1988;34(6):853–8.PubMedCrossRefGoogle Scholar
  84. 84.
    Sloand JA, Schiff MJ. Beneficial effect of low-dose transdermal estrogen on bleeding time and clinical bleeding in uremia. Am J Kidney Dis. 1995;26(1):22–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Elizabeth Schmidt
    • 1
    Email author
  • Sarah L. Pachtman
    • 2
  • Justin T. Diedrich
    • 3
  1. 1.Department of Family Planning, Department of Obstetrics and GynecologyDonald and Barbara Zucker School of Medicine at Hofstra/NorthwellManhassetUSA
  2. 2.Division of Maternal Fetal Medicine, Department of Obstetrics and GynecologyDonald and Barbara Zucker School of Medicine at Hofstra/NorthwellManhassetUSA
  3. 3.Department of Obstetrics and GynecologyUniversity of CaliforniaRiversideUSA

Personalised recommendations